Glucagonoma syndrome: Diagnosis and treatment [1]

Journal of the American Academy of Dermatology

Volumn 48, Issue 2 SUPPL., 2003, Pages 297-298

  Zeng, Jianying ^a   Wang, Baoxi ^a   Donglai, Ma ^a   Fang Li, Donglai Ma ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN;

ADULT; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; GLUCAGON BLOOD LEVEL; GLUCAGONOMA; HUMAN; IMPETIGO; LETTER; MALE; PEMPHIGUS FOLIACEUS; PRIORITY JOURNAL; SUBCORNEAL PUSTULAR DERMATOSIS;

EID: 0037329097     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2003.73     Document Type: Letter

References (4)

1. Kheir SM, Omura EF, Grizzle WE, Herrera GA, Lee I. Histologic variations in the skin lesions of the glucagonoma syndrome. Am J Surg Pathol 1986;10:445-53.
2. Hunt SJ, Narus VT, Abell E. Necrolytic migratory erythema: dyskeratotic dermatitis, a clue to early diagnosis. J Am Acad Dermatol 1991;24:473-7.
3. Altimari AF, Bhoopalam N, O'Dorsio T, Lange CL, Sandberg L, Prinz RA. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Surgery 1986;100:989-96.
4. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998;93:1468-71.